Genocea Biosciences (GNCA)
OTHER OTC:GNCA

Genocea Biosciences (GNCA) Stock Price & Analysis

0 Followers

GNCA Stock Chart & Stats

Day’s Range$0.0001 - $0.0001
52-Week Range― - ―
Previous Close$0.0011
Volume30.27K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,783,503
10 Day Avg. Volume1,057,991
30 Day Avg. Volume539,832
Standard Deviation0.27
R-Squared0.12
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1.74
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

GNCA FAQ

What was Genocea Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Genocea Biosciences’s market cap?
Currently, no data Available
When is Genocea Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genocea Biosciences’s earnings last quarter?
Currently, no data Available
Is Genocea Biosciences overvalued?
According to Wall Street analysts Genocea Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Genocea Biosciences pay dividends?
    Genocea Biosciences does not currently pay dividends.
    What is Genocea Biosciences’s EPS estimate?
    Genocea Biosciences’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Genocea Biosciences have?
    Currently, no data Available
    What happened to Genocea Biosciences’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Genocea Biosciences?
    Currently, no hedge funds are holding shares in GNCA

    ---

    Genocea Biosciences Stock Smart Score

    N/A
    Not Ranked
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
    Learn more about TipRanks Smart Score

    Company Description

    Genocea Biosciences

    Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

    ---

    Forecast EPS vs Actual EPS

    Currently, no data available
    Please return soon. This page is being updated.

    Similar Stocks
    Company
    Price & Change
    Follow
    FluoroPharma Medical
    Predictive Technology Group
    Kiwa Bio-Tech Products Group
    Cell Source
    Arno Therapeutics

    Popular Stocks

    ---
    What's Included in PREMIUM?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis